You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | -2,179.1% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -22.9 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 458.7 | n/a |
Price / Book value | 17.3 |
Latest | Forecast | |
---|---|---|
Revenue | -20.7% | n/a |
PBT | 0.0% | n/a |
EPS | 0.0% | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 0.20 | -0.53 | -5.00p | 0.0 | 0.0 | n/a | n/a | 0.0% |
2020-12-31 | 0.46 | -0.72 | -8.00p | 0.0 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 0.34 | -3.64 | -26.00p | -23.7 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 0.27 | -5.93 | -42.00p | -16.9 | 0.0 | n/a | n/a | 0.0% |
4basebio client gets approval to start trial in Australia Sharecast News | 21 Mar |
---|---|
4basebio inks significant DNA supply contract Sharecast News | 01 Mar |
First-half losses narrow for 4basebio Sharecast News | 21 Sep |
4basebio Plc - 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine | 21-Mar-24 09:18 |
---|---|
4basebio Plc - Holding(s) in Company | 06-Feb-24 07:02 |
4basebio Plc - Holding(s) in Company | 06-Feb-24 07:02 |
4basebio Plc - Holding(s) in Company | 06-Feb-24 07:02 |
4basebio Plc - Holding(s) in Company | 06-Feb-24 07:02 |